Caribou Biosciences Files 8-K on Financials and Operations

Ticker: CRBU · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1619856

Caribou Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyCaribou Biosciences, INC. (CRBU)
Form Type8-K
Filed DateNov 3, 2025
Risk Levelmedium
Pages13
Reading Time16 min
Key Dollar Amounts$0.0001, $159.2 million
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, sec-filing

Related Tickers: CRBU

TL;DR

CRBU dropped an 8-K detailing financials and operations - check it out.

AI Summary

Caribou Biosciences, Inc. filed an 8-K on November 3, 2025, reporting on its results of operations and financial condition. The filing also included disclosures under Regulation FD and other events, along with financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Berkeley, California.

Why It Matters

This 8-K filing provides investors with crucial updates on Caribou Biosciences' financial health and operational status, impacting investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant financial and operational updates that may affect a company's stock price.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates 'Results of Operations and Financial Condition' are being reported, but specific figures are not detailed in the provided text.

What is the significance of the 'Regulation FD Disclosure' item?

This indicates that the company is making disclosures that could be considered material non-public information, ensuring fair and simultaneous dissemination to all investors.

When was this 8-K filing submitted?

The filing was submitted on November 3, 2025.

What is Caribou Biosciences' primary business sector?

Caribou Biosciences, Inc. is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, SIC code 2836.

Where are Caribou Biosciences' principal executive offices located?

The principal executive offices are located at 2929 7th Street, Suite 105, Berkeley, California 94710.

Filing Stats: 4,048 words · 16 min read · ~13 pages · Grade level 18.3 · Accepted 2025-11-03 07:02:57

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On November 3, 2025, Caribou Biosciences, Inc. (the "Company") announced certain preliminary financial results for the quarter ended September 30, 2025. On a preliminary unaudited basis, the Company expects its cash, cash equivalents, and marketable securities as of September 30, 2025 to be approximately $159.2 million. This estimate of cash, cash equivalents, and marketable securities is its preliminary estimate based on currently available information and does not present all necessary information for an understanding of the Company's financial condition as of September 30, 2025, or its results of operations for the three and nine months ended September 30, 2025. As the Company completes its quarter-end financial close process and finalizes its financial statements for the three and nine months ended September 30, 2025, the Company may be required to make significant adjustments that may result in the estimate provided herein being different than the final cash, cash equivalents, and marketable securities as of September 30, 2025 to be reported in its Form 10-Q.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On November 3, 2025, the Company issued a press release announcing results from its ongoing ANTLER phase 1 trial evaluating vispacabtagene regedleucel ("vispa-cel;" formerly CB-010), an allogeneic anti-CD19 chimeric antigen receptor ("CAR")-T ("CAR-T") cell therapy, in patients with relapsed or refractory B cell non-Hodgkin lymphoma ("r/r B-NHL"). The Company also announced the planned design of its randomized, controlled pivotal phase 3 trial for vispa-cel in second-line ("2L") large B cell lymphoma ("LBCL") CD19-nave patients who are ineligible for transplant and autologous CAR-T cell therapy. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Also, on November 3, 2025, the Company issued a press release announcing data from the dose escalation portion of its ongoing CaMMouflage phase 1 trial evaluating CB-011, an allogeneic anti-B cell maturation antigen ("anti-BCMA") CAR-T cell therapy, in patients with relapsed or refractory multiple myeloma ("r/r MM"). A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein. The Company will host a live webcast today, Monday, November 3, 2025, at 8:00 a.m. Eastern Time, to discuss the clinical developments for both vispa-cel and CB-011. A copy of the slide presentation to be used during the Company's webcast is attached hereto as Exhibit 99.3 and incorporated by reference herein. Details for accessing the webcast are included in both Exhibit 99.1 and Exhibit 99.2. The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the "Securities

01 Other Matters

Item 8.01 Other Matters. Data Releases The Company is a clinical-stage C lustered R egularly I nterspaced S hort P alindromic R epeats ("CRISPR") genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The Company's genome-editing platform, including its novel chRDNA ( C RISPR h ybrid R NA- DNA , pronounced "chardonnay") technology, enables more precise genome editing of allogeneic cell therapies. The Company's allogeneic, or off-the-shelf, CAR-T cell therapy product candidates are manufactured in advance with cells from healthy donors, with the goal of enabling broad patient access, rapid patient treatment, and increased manufacturing scale. The Company's allogeneic CAR-T cell therapy product candidates in clinical development are directed at established cell surface targets against which autologous CAR-T cell therapeutics have already demonstrated clinical proof of concept, CD19 and B cell maturation antigen ("BCMA"). The Company uses its chRDNA technologies to armor its allogeneic CAR-T cell therapies through multiple genome-editing strategies, such as checkpoint disruption and immune cloaking, to enhance activity against hematologic malignancies. The Company is advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel ("vispa-cel"; formerly CB-010) : an allogeneic anti-CD19 CAR-T cell therapy that is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma ("r/r B-NHL") in the Company's ongoing ANTLER phase 1 clinical trial. The Company believes vispa-cel will have several advantages over commercially available autologous CAR-T cell therapies, including broad patient access, shorter time to treatment with an off-the-shelf product, significantly lower manufacturing costs, and a substantially smaller footprint for manufacturing. CB-011 : an allogeneic

Forward-Looking Statements

Forward-Looking Statements The disclosure in this Current Report on Form 8-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business and operations of the Company. These forward-looking statements are subject to a number of known and unknown risks, assumptions, uncertainties, and other factors that may cause the actual results, levels of activity, performance, or achievements of the Company to be materially different from those expressed or implied by any forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "likely," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential," "contribute to," or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements, other than statements of historical facts contained in this presentation, are forward-looking statements, including but not limited to any statements regarding the initiation, timing, progress, strategy, plans, objectives, expectations (including as to the results) with respect to the Company's CAR-T cell therapy product candidate clinical trials, including the expected design, protocol, and timing of initiation of the pivotal phase 3 clinical trial for vispa-cel in 2L LBCL CD19-nave patients; its expectations and timing of initiating dose expansion by the end of 2025 and reporting dose expansion data, along with longer follow-up data on dose escalation, in 2026 from its ongoing CaMMouflage Phase 1 clinical trial for CB-011 in patients with r/r MM; the projected manufacturing costs for its CAR-T cell therapy product candidates; the potential commercial opportunities for its CAR-T cell therapy product candidates; the likelihood of its clinical trials demonstrating safety and efficacy of its CAR-T

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release Issued by Caribou Biosciences, Inc. on November 3 , 2025 99.2 Press Release Issued by Caribou Biosciences, Inc. on November 3 , 2025 99.3 Caribou Biosciences, Inc. Positive clinical updates on Caribou's off-the-shelf CAR-T cell therapy programs: vispa-cel for r/r LBCL (vispacabtagene regedleucel; CB-010) and CB-011 for r/r MM – November 3 , 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Caribou Biosciences, Inc. Date: November 3, 2025 By: /s/ Rachel E. Haurwitz Rachel E. Haurwitz President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing